EC Healthcare Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Leslie Lu
Chief executive officer
HK$4.8m
Total compensation
| CEO salary percentage | 99.63% |
| CEO tenure | 2.4yrs |
| CEO ownership | n/a |
| Management average tenure | 5yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Is EC Healthcare (HKG:2138) Using Too Much Debt?
Jan 30
A Piece Of The Puzzle Missing From EC Healthcare's (HKG:2138) 28% Share Price Climb
Aug 06EC Healthcare's (HKG:2138) Returns On Capital Not Reflecting Well On The Business
Jun 19EC Healthcare's (HKG:2138) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 20Does EC Healthcare (HKG:2138) Have A Healthy Balance Sheet?
Feb 11EC Healthcare (HKG:2138) Shares Fly 29% But Investors Aren't Buying For Growth
Dec 18EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends
Nov 13Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding
Sep 05EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively
Jul 26EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 13When Should You Buy EC Healthcare (HKG:2138)?
Apr 26Is EC Healthcare (HKG:2138) A Risky Investment?
Feb 07Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch
Dec 24EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005
Dec 08Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital
Dec 01At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?
Sep 15EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042
Aug 24Is EC Healthcare (HKG:2138) Using Too Much Debt?
Aug 10EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042
Jul 14EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042
Jun 26Is There Now An Opportunity In EC Healthcare (HKG:2138)?
Jun 15Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital
May 12Is EC Healthcare (HKG:2138) Potentially Undervalued?
Mar 08EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends
Feb 03EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year
Dec 20Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?
Oct 25EC Healthcare (HKG:2138) Is Reinvesting At Lower Rates Of Return
Sep 20EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042
Sep 01EC Healthcare's (HKG:2138) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 28EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042
Jul 14EC Healthcare (HKG:2138) Is Reducing Its Dividend To HK$0.042
Jun 26When Should You Buy EC Healthcare (HKG:2138)?
May 26EC Healthcare (HKG:2138) Will Be Hoping To Turn Its Returns On Capital Around
Apr 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -HK$192m |
| Jun 30 2025 | n/a | n/a | -HK$179m |
| Mar 31 2025 | HK$5m | HK$5m | -HK$167m |
| Dec 31 2024 | n/a | n/a | -HK$89m |
| Sep 30 2024 | n/a | n/a | -HK$12m |
| Jun 30 2024 | n/a | n/a | -HK$15m |
| Mar 31 2024 | HK$5m | HK$5m | -HK$19m |
| Dec 31 2023 | n/a | n/a | -HK$11m |
| Sep 30 2023 | n/a | n/a | -HK$4m |
| Jun 30 2023 | n/a | n/a | HK$33m |
| Mar 31 2023 | HK$21m | HK$4m | HK$70m |
| Dec 31 2022 | n/a | n/a | HK$93m |
| Sep 30 2022 | n/a | n/a | HK$117m |
| Jun 30 2022 | n/a | n/a | HK$157m |
| Mar 31 2022 | HK$13m | HK$2m | HK$198m |
Compensation vs Market: Leslie's total compensation ($USD615.06K) is above average for companies of similar size in the Hong Kong market ($USD242.64K).
Compensation vs Earnings: Leslie's compensation has been consistent with company performance over the past year.
CEO
Leslie Lu (45 yo)
Mr. Lyn Wade Lu, also known as Leslie, served as Co-Chief Executive Officer & Executive Director at EC Healthcare since August 23, 2021 until November 1, 2023. He serves as Chief Executive Officer at EC He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 10.4yrs | HK$1.22m | 60.93% HK$ 343.0m | |
| CEO & Executive Director | 2.4yrs | HK$4.82m | no data | |
| CFO & Executive Director | 6.8yrs | HK$3.77m | 0.057% HK$ 323.3k | |
| Chief Public Affairs Officer | no data | no data | no data | |
| Chief Proposition Officer of Healthcare | 3.3yrs | no data | no data | |
| Company Secretary | 8.6yrs | no data | no data |
Experienced Management: 2138's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 10.4yrs | HK$1.22m | 60.93% HK$ 343.0m | |
| CEO & Executive Director | 4.7yrs | HK$4.82m | no data | |
| CFO & Executive Director | 6.3yrs | HK$3.77m | 0.057% HK$ 323.3k | |
| Independent Non-Executive Director | 10.2yrs | HK$240.00k | 0.025% HK$ 142.5k | |
| Independent Non-Executive Director | 10.2yrs | HK$220.00k | no data | |
| Non Executive Director | 10.6yrs | HK$120.00k | 0.24% HK$ 1.3m | |
| Independent Non-Executive Director | 3.6yrs | HK$120.00k | no data | |
| Non-Executive Director | 1.3yrs | HK$32.00k | 0.65% HK$ 3.6m |
Experienced Board: 2138's board of directors are considered experienced (8.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 22:54 |
| End of Day Share Price | 2026/04/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EC Healthcare is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhuonan Xu | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |
| null null | CMB International Securities Limited |